Synklino, a Copenhagen, a Denmark-based biotech company developing new drugs for the treatment of chronic viral infections, raised EUR 29.8M in Series A funding.
The company is owned by renowned Nordic funds and institutional investors Eir Ventures, The Danish Growth Fund and PKA as well as approximately 70 private shareholders.
Led by CEO Thomas Kledal, Synklino is a biotech company developing therapies against chronic viral infections.
The company intends to use the funds to advance its drug candidate SYN002 for the treatment of Cytomegalovirus (CMV), into both ex vivo and in vivo Phase 1 clinical trials and generate safety and efficacy data establishing a solid foundation for expanding its pipeline, and widening the strategic options for further value creation.
Human cytomegalovirus (CMV) is a β-herpes virus. CMV is a widespread, chronic viral infection found in more than 60% of adults worldwide. Initial infection in otherwise healthy immunocompetent individuals results in productive (lytic) infection and is almost always asymptomatic. Like all other herpes viruses, CMV establishes lifelong latent infection and incorporates its DNA into host cells. CMV reactivation from latency is a serious issue in transplant patients due to the need for concomitant immunosuppressive therapy. Active infection and accumulation of a high virus load in immunosuppressed patients leads to a variety of CMV diseases, including organ rejection, developmental and neurological complications, and can be fatal. CMV has a major impact on morbidity and mortality during transplantation and increases transplant costs by up to 50% due to long-term hospitalizations and difficult courses of treatment. The treatment of CMV therefore represents a large unmet medical need. No currently marketed or pipeline drugs can cure CMV, and current drugs pose a risk of developing resistance.
FinSMEs
09/06/2022